Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading VALN daily closes…
Loading price history…
Pipeline assets
VLA15
Phase 3 · ActiveModality: vaccine
Target Borrelia burgdorferi
Partnerships Pfizer: conducts VALOR Phase 3; sole discretion over regulatory submissions, marketing, and commercialization; milestone and royalty revenue expected
Indications
Lyme disease(Phase 3)
Catalysts
— H1 2026
— 2026
— 2027 or 2028
Status note Pivotal placebo-controlled efficacy trial (VALOR) conducted by Pfizer. Company plans restructuring/cost containment if primary endpoints not met.
VLA1553
Approved · ActiveModality: vaccine
Aliases IXCHIQ
Target Chikungunya virus
Partnerships Instituto Butantan: manufacturing/commercialization in low- and middle-income countries; Serum Institute of India agreement terminated end 2025 (seeking new Asia partner for manufacturing/marketing/distribution)
Indications
Chikungunya(Stage not disclosed)
Status note 2025 sales below expectations following reports of serious adverse events and subsequent regulatory action. Pursuing approvals in additional markets.
S4V2
Phase 2 · ActiveModality: vaccine
Target Shigella
Indications
Shigellosis(Phase 2)
Status note Ongoing Phase 2 trials.
Per-asset detail extracted from the 20-F filed 2026-03-17. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
Frazier Life Sciences
2,291,666
no change
0.26%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.